Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer

被引：1
|
作者：
Whittle, J. R.
Vaillant, F.
Policheni, A. N.
Liu, K.
Pal, B.
Giner, G.
Fernandez, K.
Gray, D. H.
Caldon, C. E.
Smyth, G. K.
Visvader, J. E.
Lindeman, G. J.
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Garvan Inst Med Res, Sydney, NSW, Australia
[5] Univ New South Wales, Sydney, NSW, Australia
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD7-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD7-07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CDK4/6 inhibition in HER2-positive breast cancer Comment
    Battisti, Nicolo Matteo Luca
    Ring, Alistair
    LANCET ONCOLOGY, 2020, 21 (06): : 734 - 735
  • [32] Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
    Vaillant, Francois
    Merino, Delphine
    Lee, Lily
    Breslin, Kelsey
    Pal, Bhupinder
    Ritchie, Matthew E.
    Smyth, Gordon K.
    Christie, Michael
    Phillipson, Louisa J.
    Burns, Christopher J.
    Mann, G. Bruce
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    CANCER CELL, 2013, 24 (01) : 120 - 129
  • [33] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
    Gomes, Ines
    Abreu, Catarina
    Costa, Luis
    Casimiro, Sandra
    CANCERS, 2023, 15 (19)
  • [34] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
  • [35] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
    Hehui Fang
    Doudou Huang
    Fang Yang
    Xiaoxiang Guan
    Breast Cancer Research and Treatment, 2018, 168 : 287 - 297
  • [36] Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer
    Witkiewicz, Agnieszka
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
    Fang, Hehui
    Huang, Doudou
    Yang, Fang
    Guan, Xiaoxiang
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : CP8 - 297
  • [38] CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond
    Layman, Rachel M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02): : 190 - 192
  • [39] CDK4/6 inhibition blocks effects of IGFs and insulin in estrogen receptor positive and triple negative breast cancers
    Hoff, Katelyn
    Sachdev, Deepali
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
    Richard S. Finn
    Alexey Aleshin
    Dennis J. Slamon
    Breast Cancer Research, 18
12345